259 related articles for article (PubMed ID: 24648510)
1. Physiological IgM class catalytic antibodies selective for transthyretin amyloid.
Planque SA; Nishiyama Y; Hara M; Sonoda S; Murphy SK; Watanabe K; Mitsuda Y; Brown EL; Massey RJ; Primmer SR; O'Nuallain B; Paul S
J Biol Chem; 2014 May; 289(19):13243-58. PubMed ID: 24648510
[TBL] [Abstract][Full Text] [Related]
2. Hydrolysis and Dissolution of Amyloids by Catabodies.
Meretoja VV; Paul S; Planque SA
Methods Mol Biol; 2017; 1643():111-134. PubMed ID: 28667533
[TBL] [Abstract][Full Text] [Related]
3. Constant domain-regulated antibody catalysis.
Sapparapu G; Planque S; Mitsuda Y; McLean G; Nishiyama Y; Paul S
J Biol Chem; 2012 Oct; 287(43):36096-104. PubMed ID: 22948159
[TBL] [Abstract][Full Text] [Related]
4. Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.
Galant NJ; Bugyei-Twum A; Rakhit R; Walsh P; Sharpe S; Arslan PE; Westermark P; Higaki JN; Torres R; Tapia J; Chakrabartty A
Sci Rep; 2016 Apr; 6():25080. PubMed ID: 27122057
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120.
Paul S; Karle S; Planque S; Taguchi H; Salas M; Nishiyama Y; Handy B; Hunter R; Edmundson A; Hanson C
J Biol Chem; 2004 Sep; 279(38):39611-9. PubMed ID: 15269209
[TBL] [Abstract][Full Text] [Related]
6. Catalytic antibody (catabody) platform for age-associated amyloid disease: From Heisenberg's uncertainty principle to the verge of medical interventions.
Planque SA; Massey RJ; Paul S
Mech Ageing Dev; 2020 Jan; 185():111188. PubMed ID: 31783036
[TBL] [Abstract][Full Text] [Related]
7. Specific amyloid β clearance by a catalytic antibody construct.
Planque SA; Nishiyama Y; Sonoda S; Lin Y; Taguchi H; Hara M; Kolodziej S; Mitsuda Y; Gonzalez V; Sait HB; Fukuchi K; Massey RJ; Friedland RP; O'Nuallain B; Sigurdsson EM; Paul S
J Biol Chem; 2015 Apr; 290(16):10229-41. PubMed ID: 25724648
[TBL] [Abstract][Full Text] [Related]
8. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
9. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.
Taguchi H; Planque S; Nishiyama Y; Szabo P; Weksler ME; Friedland RP; Paul S
Autoimmun Rev; 2008 May; 7(5):391-7. PubMed ID: 18486927
[TBL] [Abstract][Full Text] [Related]
10. Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils.
Phay M; Blinder V; Macy S; Greene MJ; Wooliver DC; Liu W; Planas A; Walsh DM; Connors LH; Primmer SR; Planque SA; Paul S; O'Nuallain B
Rejuvenation Res; 2014 Apr; 17(2):97-104. PubMed ID: 24164623
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Soluble Oligomeric and Aggregated Transthyretin with a Monoclonal Antibody Ameliorates Experimental Neuropathy.
Fassler M; Tshori S; Barac Y; Bowles DE; Benaim C; George J
Biology (Basel); 2022 Oct; 11(10):. PubMed ID: 36290413
[TBL] [Abstract][Full Text] [Related]
12. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
[TBL] [Abstract][Full Text] [Related]
13. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants.
Goldsteins G; Persson H; Andersson K; Olofsson A; Dacklin I; Edvinsson A; Saraiva MJ; Lundgren E
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3108-13. PubMed ID: 10077645
[TBL] [Abstract][Full Text] [Related]
14. Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.
Paul S; Planque S; Nishiyama Y
J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S43-9. PubMed ID: 20454852
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations.
Gustavsson A; Engström U; Westermark P
Am J Pathol; 1994 Jun; 144(6):1301-11. PubMed ID: 8203468
[TBL] [Abstract][Full Text] [Related]
16. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.
Schonhoft JD; Monteiro C; Plate L; Eisele YS; Kelly JM; Boland D; Parker CG; Cravatt BF; Teruya S; Helmke S; Maurer M; Berk J; Sekijima Y; Novais M; Coelho T; Powers ET; Kelly JW
Sci Transl Med; 2017 Sep; 9(407):. PubMed ID: 28904227
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
18. Proposing a minimal set of metrics and methods to predict probabilities of amyloidosis disease and onset age in individuals.
Criddle RS; Lin HL; James I; Park JS; Hansen LD; Price JC
Aging (Albany NY); 2020 Nov; 12(22):22356-22369. PubMed ID: 33203794
[TBL] [Abstract][Full Text] [Related]
19. Autoantibody-catalyzed hydrolysis of amyloid beta peptide.
Taguchi H; Planque S; Nishiyama Y; Symersky J; Boivin S; Szabo P; Friedland RP; Ramsland PA; Edmundson AB; Weksler ME; Paul S
J Biol Chem; 2008 Feb; 283(8):4714-22. PubMed ID: 18086674
[TBL] [Abstract][Full Text] [Related]
20. Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody.
Teixeira AC; Saraiva MJ
Amyloid; 2023 Mar; 30(1):74-80. PubMed ID: 36111397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
